TYRVAYA
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.3M | 19,194 | 8,562 |
| 2023 | $1.9M | 27,775 | 10,902 |
| 2022 | $1.9M | 25,832 | 11,583 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.2M | 827 | 43.2% |
| Food and Beverage | $2.0M | 70,191 | 39.3% |
| Consulting Fee | $372,656 | 238 | 7.2% |
| Travel and Lodging | $281,551 | 1,523 | 5.5% |
| Unspecified | $205,852 | 10 | 4.0% |
| Honoraria | $28,725 | 8 | 0.6% |
| Space rental or facility fees (teaching hospital only) | $6,000 | 2 | 0.1% |
| Grant | $5,000 | 1 | 0.1% |
| Education | $3,500 | 1 | 0.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Single-arm Investigator Initiated Study to Evaluate the Efficacy of OC-01 (varenicline solution) Nasal Spray on and symptoms of Dry Eye Disease in subjects with Sjogrens Syndrome (The SENSation Study) | Oyster Point Pharma, Inc. | $98,922 | 0 |
| A Randomized, Controlled, Double-masked, Investigator-initiated Trial to Evaluate Tear Film Quality and Stability in Subjects With Dry Eye Disease Using OC-01 (Varenicline Solution) Nasal Spray 0.03 mg as Compared to Vehicle Control Nasal Spray | Oyster Point Pharma, Inc. | $68,977 | 0 |
| A Phase 4, Single-Center, Open-Label Study Evaluating the Safety of the Tyrvaya Nasal Pump | Oyster Point Pharma, Inc. | $18,692 | 0 |
| Retrospective Study with Tyrvaya and Sjogren's Syndrome | Oyster Point Pharma, Inc. | $14,260 | 0 |
| Randomized, Controlled, Double-masked Investigator Initiated Study to Evaluate the Efficacy of OC-01 (varenicline) Nasal Spray on Objective and Subjective Dry Eye signs and sumptoms in Daily Disposable Contact Lens Wearers | Oyster Point Pharma, Inc. | $5,000 | 0 |
Top Doctors Receiving Payments for TYRVAYA — Page 735
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Mark Esarey | — | Charleston, IL | $11.75 | 1 |
| , M.D | Ophthalmology | Cleveland, OH | $11.75 | 1 |
| , OD | Optometrist | Plymouth, MA | $11.75 | 1 |
| Marc Wladis | — | N Dartmouth, MA | $11.74 | 1 |
| , O.D. PA | Optometrist | Brooksville, FL | $11.74 | 1 |
| , O.D | Optometrist | Yonkers, NY | $11.72 | 1 |
| , O.D | Optometrist | Far Rockaway, NY | $11.72 | 1 |
| Mark Golden | — | Schaumburg, IL | $11.70 | 1 |
| , MD | Ophthalmology | Parkersburg, WV | $11.70 | 1 |
| , O.D | Optometrist | Buford, GA | $11.70 | 1 |
| , OD | Optometrist | Greenville, SC | $11.69 | 1 |
| , O.D | Optometrist | Baxter, MN | $11.68 | 1 |
| Brett Hollenbach | Optometrist | Columbus, OH | $11.68 | 1 |
| , O.D | Optometrist | Wethersfield, CT | $11.64 | 1 |
| , OD | Optometrist | Keene, NH | $11.64 | 1 |
| , M.D | Ophthalmology | Hollywood, FL | $11.64 | 1 |
| , O.D | Optometrist | Feasterville Trevose, PA | $11.64 | 1 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $5.2M
- Total Doctors 18,366
- Transactions 72,801
About TYRVAYA
TYRVAYA is a drug associated with $5.2M in payments to 18,366 healthcare providers, recorded across 72,801 transactions in the CMS Open Payments database. The primary manufacturer is Oyster Point Pharma, Inc..
Payment data is available from 2022 to 2024. In 2024, $1.3M was paid across 19,194 transactions to 8,562 doctors.
The most common payment nature for TYRVAYA is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.2M, 43.2% of total).
TYRVAYA is associated with 5 research studies, including "A Single-arm Investigator Initiated Study to Evaluate the Efficacy of OC-01 (varenicline solution) Nasal Spray on and symptoms of Dry Eye Disease in subjects with Sjogrens Syndrome (The SENSation Study)" ($98,922).